LabCorp

CND Life Sciences specializes in developing diagnostic tools for neurodegenerative diseases, particularly focusing on synucleinopathy. The company has introduced the Syn-One Test, which is designed to detect, visualize, and quantify abnormal phosphorylated alpha-synuclein in cutaneous nerve fibers. This commercially available test serves as an objective diagnostic aid for confirming synucleinopathy in patients suspected of having conditions such as Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, or pure autonomic failure. By providing a convenient and minimally invasive method for diagnosis, CND Life Sciences enhances the ability of medical professionals to accurately identify these complex disorders.

Olaris is dedicated to transforming disease diagnosis and treatment through its innovative CEREBRO platform, which integrates metabolomics and machine learning. This platform focuses on the Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes, enabling the identification of biomarkers that can optimize patient treatment. By developing the myOLARIS™ precision diagnostics, Olaris aims to match the right drug to the right patient, enhancing clinical outcomes while minimizing adverse events. Founded in 2013 and headquartered in Framingham, Massachusetts, the company collaborates with healthcare providers to improve patient care through advanced diagnostic solutions.

BioReference Health - Laboratory Testing Businesses focused on oncology and oncology-related clinical testing services.

Percipio Health specializes in utilizing artificial intelligence to provide insights that assist clinicians and caregivers in maintaining a comprehensive understanding of a patient's health. The company has developed a platform that enhances the capabilities of computer vision software, allowing healthcare providers to accurately assess patient health status and identify medications. This technology empowers healthcare professionals to make informed decisions regarding patient care, ultimately improving health outcomes.

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

Praia Health is a cutting-edge consumer platform for health systems that transforms the delivery of personalised health solutions on a large scale, allowing digital transformation.

PreciseDx is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient. Combining the power of artificial intelligence with its proprietary Morphology Feature Array™, PreciseDx creates disease-specific assays that deliver new levels of pathology information and insight on each patient's risk profile and likely outcomes to aid in treatment decision-making.

NOWDiagnostics, Inc. is a company based in Springdale, Arkansas, that specializes in the development and manufacturing of blood-based rapid diagnostic tests. Founded in 2013, the company offers innovative testing solutions that require only a single drop of blood, providing results within minutes. This approach empowers both patients and caregivers by enabling timely decision-making regarding healthcare. NOWDiagnostics' product line, ADEXUSDx, includes tests for various conditions such as pregnancy, cardiac events, and toxicology, all designed to be conducted in-home or in-clinic without the need for off-site laboratory processing. The company aims to reduce the waiting time for test results, enhancing the overall efficiency of medical diagnostics. NOWDiagnostics collaborates with strategic partners, including Zalgen Labs LLC, to expand its offerings in the diagnostic market.

Acclinate is a venture-backed company focused on enhancing representation and diversity in genomic research and clinical trials through its digital health platform. By utilizing machine learning and predictive analytics, Acclinate automates the processes of identifying, educating, engaging, and retaining diverse participants for research studies. This approach not only empowers communities to improve their health outcomes but also helps biopharmaceutical organizations reduce the overall costs associated with drug development. Through sustained engagement and AI-driven insights, Acclinate aims to foster better health practices and outcomes within underrepresented populations.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Prolocor is a biotechnology company founded in 2020 and based in Philadelphia, Pennsylvania, specializing in the development of diagnostic tests for cardiovascular diseases. The company focuses on creating a precise method to assess and manage the risk associated with these conditions. Prolocor's primary product quantifies platelet FcγRIIa to identify patients at varying levels of risk for heart attack, stroke, and cardiovascular death. Utilizing flow cytometry, the tests measure the number of FcγRIIa molecules per platelet, which assists healthcare providers in optimizing treatment strategies to minimize bleeding and reduce the likelihood of recurrent thrombotic events.

Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.

AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that will improve clinical practice and help reduce patient mortality.

Baystate Health is an integrated healthcare delivery system that serves nearly one million residents in western Massachusetts. It comprises multiple hospitals and ancillary services, aiming to provide comprehensive medical care to the community. In addition to its healthcare services, the Baystate Health Foundation, established in 2000 and based in Springfield, supports the organization through philanthropic efforts. This independent non-profit foundation focuses on fundraising for healthcare-related activities, benefiting Baystate Health and its subsidiaries, which are designated as tax-exempt, not-for-profit entities. The foundation manages its investments through its executive management team, ensuring that charitable donations and endowments effectively support the healthcare needs of the community.

Evvy is a company focused on improving female health by offering at-home vaginal microbiome tests. These tests utilize metagenomic sequencing to analyze symptoms and identify risks associated with important health issues. By providing personalized reports, Evvy aims to empower women with insights about their bodies, thereby addressing the gender health gap and enhancing overall health outcomes for women.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Vital Bio is focused on transforming lab testing to make healthcare more accessible and personalized. The company develops advanced diagnostic technologies that connect diagnosis and treatment through a comprehensive ecosystem of devices, software, and services. By empowering patients to monitor their health and manage diseases, Vital Bio aims to enhance the overall healthcare experience. Their approach seeks to reduce disparities in healthcare outcomes and redistribute control to patients while equipping healthcare providers with the tools necessary to achieve better results.

Prognos Health is a health tech company focused on healthcare analytics, offering a platform called prognosFACTOR. This innovative platform can quickly query billions of lab and health records from over 325 million de-identified patients, providing answers to clinically relevant healthcare questions in a fraction of the time traditionally required. Prognos Health allows clients to access HIPAA-compliant, patient-centric healthcare data through the Prognos Marketplace, facilitating a range of applications such as cohort design, patient journey studies, and health outcomes analysis. The company's clientele includes 25 of the top 30 pharmaceutical manufacturers and three of the top five health payers, highlighting its significant role in empowering precise decision-making throughout the healthcare landscape.

Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

Mercy BioAnalytics is a biotechnology company based in Natick, Massachusetts, founded in 2018 by Paul Blavin and Joseph Sedlak. The company focuses on improving cancer outcomes through early detection by utilizing a novel liquid biopsy assay platform. This platform analyzes tumor-derived extracellular vesicles (EVs), which are abundant in blood and provide critical information about their parent cells. By leveraging these EVs, Mercy BioAnalytics aims to enable the detection of various types of cancer at its earliest stages, ultimately striving to enhance patient outcomes and save lives.

Clinical Outreach Laboratory Services provides all medical and clinical trials.

Prolocor is a biotechnology company founded in 2020 and based in Philadelphia, Pennsylvania, specializing in the development of diagnostic tests for cardiovascular diseases. The company focuses on creating a precise method to assess and manage the risk associated with these conditions. Prolocor's primary product quantifies platelet FcγRIIa to identify patients at varying levels of risk for heart attack, stroke, and cardiovascular death. Utilizing flow cytometry, the tests measure the number of FcγRIIa molecules per platelet, which assists healthcare providers in optimizing treatment strategies to minimize bleeding and reduce the likelihood of recurrent thrombotic events.

Epic Sciences is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells ("CTCs"). Epic is working with a number of partners including numerous pharmaceutical companies, major cancer centers, the National Cancer Institute, and the National Institutes of Health.

Circuit Clinical is an integrated research organization that facilitates participation in clinical research for patients and healthcare providers. Founded in 2015, it emerged from the experiences of a physician who recognized the importance of trust in the clinical research process. Circuit Clinical focuses on enhancing physician and participant engagement, leveraging HIPAA and FDA-compliant Electronic Medical Record (EMR) reviews to identify motivated participants. The organization provides a suite of technology products designed to improve the clinical research experience for both participants and physicians. By connecting a network of over one million patients with community physicians and research sponsors, Circuit Clinical aims to improve site quality and patient safety, making clinical research more accessible and navigable for all involved.

Getlabs, Inc. is a digital health platform based in Santa Monica, California, that specializes in at-home diagnostics. Founded in 2018, the company facilitates the scheduling of home lab appointments, where mobile phlebotomists visit patients to collect blood samples and other diagnostic tests. These samples are then delivered to laboratories for processing, allowing healthcare organizations to enhance patient care and adherence by providing same-day, nationwide service. Getlabs aims to bridge the gap between virtual and in-person healthcare, thereby improving access to essential diagnostic services. The company has secured $50 million in funding from strategic investors, including major diagnostic laboratories.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

PetDx is a San Diego-based molecular diagnostics company focused on enhancing pet health through advanced genomic technologies. The company's primary offering, OncoK9, is a pioneering multi-cancer early detection test that allows veterinarians to identify cancer in dogs through a simple blood draw. This first-in-class liquid biopsy utilizes next-generation sequencing and proprietary bioinformatics to analyze genetic material, facilitating early detection, characterization, and management of cancer in pets. By providing a non-invasive testing option, PetDx supports veterinarians in delivering improved care and outcomes for canine patients.

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

Ovia Health offers a comprehensive maternity and family benefits solution that transforms the way women and families are supported throughout the parenthood journey. The company is formerly known as Ovuline is making healthcare a lifestyle. Its mobile apps, Ovia Fertility and Ovia Pregnancy, have helped millions of women start their families and live healthier lives.

OmniSeq is a molecular diagnostic laboratory based in Buffalo, New York, founded in 2015 as an innovation of Roswell Park Cancer Institute. The company specializes in providing actionable tumor-profiling information to physicians and their patients, aiming to identify the most suitable drug or clinical trial for each individual. OmniSeq offers New York State CLEP-approved assays, including the OmniSeq Comprehensive, a 144-gene next-generation sequencing assay that detects nearly all known genetic alterations tied to FDA-approved targeted therapies or genotype-directed clinical trials. The company also focuses on enhancing diagnostics for immuno-oncology therapy selection. By leveraging advanced molecular therapy technologies, including a proprietary algorithm that minimizes false positives, OmniSeq strives to improve access to cancer treatment options through precise and comprehensive molecular profiling.

Biospectal is a company focused on remote patient monitoring and biosensing, having developed the OptiBP smartphone app and data platform for blood pressure measurement. This innovative app allows users to measure their blood pressure using the built-in camera of a smartphone, capturing blood flow through the fingertip in a quick and easy manner. The measurement process takes approximately 20 seconds, which is significantly faster than traditional blood pressure cuffs. Biospectal’s proprietary algorithms analyze the optical signals captured by the camera to provide accurate blood pressure readings. Currently, the public beta of the OptiBP app for Android is available in several countries, including the United States, the United Kingdom, France, Germany, Spain, and Switzerland. This technology empowers individuals to monitor their blood pressure anytime and anywhere, transforming smartphones into medical-grade devices without the need for additional peripherals.

PathAI, Inc. is a company that develops artificial intelligence-based technology solutions aimed at enhancing the accuracy and efficiency of pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI's platform utilizes machine and deep learning techniques to process large datasets, enabling pathologists to diagnose cancer and other conditions rapidly and accurately. The technology not only assists in making precise diagnoses but also identifies patients who may benefit from innovative therapies, thereby facilitating personalized medicine. PathAI addresses complex challenges in pathology for both the research and pharmaceutical industries, providing reliable and scalable solutions.

Advanced Animal Diagnostics, Inc. focuses on the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Based in Durham, North Carolina, the company offers products such as the QScout Farm Lab, an analyzer system that identifies infections in dairy cows before symptoms manifest, and the QScout Milk Leukocyte Differential rapid test, which analyzes milk to detect and differentiate white blood cells indicative of mastitis. Additionally, Advanced Animal Diagnostics provides solutions like QuickSmear, a rapid differential slide that aids in animal research, and the SCC+ System for early mastitis detection. These diagnostic tools are designed to enhance animal health management, benefiting veterinarians and livestock producers by enabling timely detection of infections and supporting informed treatment decisions. Founded in 2001, the company aims to improve the overall health and productivity of production animals.

Vectra is a non-invasive, blood-based test that analyzes 12 biomarkers to measure RA disease activity. It combines those measures to generate an easy-to-understand score, which indicates the severity of RA inflammation and how well current treatments are working. It also can predict potential, future joint damage. This enables the 5,000 practicing rheumatologists in the U.S. to provide targeted treatment and adjust existing treatments to better manage RA symptoms

Presage has developed a means of assessing tumor response to drugs or RNA interference agents without the limitations inherent to systemic administration. The Presage clinical surrogate approach enables drug companies to halt development projects for compounds that show no efficacy in the native tumor microenvironment. In addition, the Presage approach can identify drug targets using RNA interference without concern regarding localization or distribution of systemically administered RNAi agents. Presage technology can also be used to identify effective drug combinations in ways that more directly measure the efficacy of such combinations than otherwise possible.

Circuit Clinical is an integrated research organization that facilitates participation in clinical research for patients and healthcare providers. Founded in 2015, it emerged from the experiences of a physician who recognized the importance of trust in the clinical research process. Circuit Clinical focuses on enhancing physician and participant engagement, leveraging HIPAA and FDA-compliant Electronic Medical Record (EMR) reviews to identify motivated participants. The organization provides a suite of technology products designed to improve the clinical research experience for both participants and physicians. By connecting a network of over one million patients with community physicians and research sponsors, Circuit Clinical aims to improve site quality and patient safety, making clinical research more accessible and navigable for all involved.

Dorsata enables healthcare providers to make better decisions that are informed by data and best practices. The company provides teams of clinicians tools to build, share, and then use defined workflows, called care pathways, for efficient decision-making, documentation, and order entry. Leveraging these clinician-developed care pathways, Dorsata is committed to transforming healthcare from a cost-reduction and quality improvement standpoint. Dorsata was founded in 2011 and is headquartered in Washington, District of Columbia, United States.

PathAI, Inc. is a company that develops artificial intelligence-based technology solutions aimed at enhancing the accuracy and efficiency of pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI's platform utilizes machine and deep learning techniques to process large datasets, enabling pathologists to diagnose cancer and other conditions rapidly and accurately. The technology not only assists in making precise diagnoses but also identifies patients who may benefit from innovative therapies, thereby facilitating personalized medicine. PathAI addresses complex challenges in pathology for both the research and pharmaceutical industries, providing reliable and scalable solutions.

Navigating Cancer owns and operates a Website for cancer patients and their supporters that allow them to read about the disease, discuss ailments with others, organize personal health records, and track medications and treatments. Navigating Cancer’s mission is to transform healthcare through patient-centered care by using technology to connect every cancer patient to their healthcare team, their own health records, and the right information at the right time. Navigating Cancer’s Patient Engagement Portal provides oncology clinics with a branded, online extension of their care model and helps them save time and money while providing better quality care. The company was founded in 2008 and is based in Seattle, Washington.

Weavr Health is transforming blood collection by enabling patients to collect clinical-grade blood samples in their own homes without the need for a phlebotomist. The company has developed a self-collection device that allows average users to perform complex sample processing steps without requiring trained professionals or specialized laboratory equipment. This innovation simplifies the diagnostic testing process, making it more efficient and accessible at the point of care. By focusing on user-friendly solutions, Weavr Health aims to enhance the healthcare experience and streamline blood collection procedures.

Sandstone Diagnostics is a Bay Area biotech company developing instruments and consumables for point-of-care medical testing. Sandstone’s lead product, Trak, is a consumer semen analysis platform that provides a simple and accurate way to monitor sperm quality from the comfort of home. Trak is a tool for men to take charge of their fertility, boost their sperm quality, and improve their chances of conception. Sandstone was co-founded in 2012 by Ph.D. scientists developing medical technologies for national defense applications at Sandia National Laboratories.

Kiyatec, LLC is a biotechnology company based in Greenville, South Carolina, specializing in the development of advanced 3D cell-based assays for preclinical drug discovery and clinical therapy applications. The company utilizes patients' own living tumor cells to create functional 3D models that facilitate testing of various cancer therapies, enhancing the predictive accuracy of drug responses. Its innovative 3DKUBE technology platform supports in situ imaging and accommodates different scaffold materials, allowing for the modeling of complex human biology through segregated cell co-culture. Kiyatec's services include drug response profiling, toxicity evaluation, and the development of cell-based models for testing small molecules, biologic drugs, and immunotherapies. The company also engages in contract research projects and collaborates with the National Cancer Institute to advance research on cancer types such as breast cancer, glioblastoma, and lung cancer. Founded in 2005, Kiyatec aims to assist medical practitioners in identifying effective treatments for cancer patients by providing insights prior to clinical trials.

Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

MC10, Inc. specializes in the development and sale of wearable medical sensors designed to collect clinical-grade biometric and physiological data, primarily for use in clinical trials. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of products, including BioStamp nPoint, which processes raw data into clinical metrics such as vital signs and sleep patterns; Kintinuum, an orthopedic rehabilitation device; WiSP, a cardiac monitoring solution; and BioStampMD, a conformable sensor for gathering both objective and subjective health data. MC10 focuses on creating flexible, lightweight electronics that conform to the human body, allowing for discreet and comfortable data collection in various settings. Its proprietary BioStamp system enhances the ability to gather real-world data on muscle activation and movement, thereby advancing digital healthcare services across multiple sectors, including sports and military applications.

OmniSeq is a molecular diagnostic laboratory based in Buffalo, New York, founded in 2015 as an innovation of Roswell Park Cancer Institute. The company specializes in providing actionable tumor-profiling information to physicians and their patients, aiming to identify the most suitable drug or clinical trial for each individual. OmniSeq offers New York State CLEP-approved assays, including the OmniSeq Comprehensive, a 144-gene next-generation sequencing assay that detects nearly all known genetic alterations tied to FDA-approved targeted therapies or genotype-directed clinical trials. The company also focuses on enhancing diagnostics for immuno-oncology therapy selection. By leveraging advanced molecular therapy technologies, including a proprietary algorithm that minimizes false positives, OmniSeq strives to improve access to cancer treatment options through precise and comprehensive molecular profiling.

The Recovery Platform is a substance use specific platform that facilitates and guides physician and patient compliance when practicing MAT (Medicine Assisted Treatment).

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

PAML is a healthcare solutions company with a focus in diagnostics. It proudly serve physicians, hospitals, members of the community, employers, and other allied health professionals.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on developing diagnostic tests that assess a woman's individual risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy-related complications. Founded in 2008, Sera aims to improve maternal and neonatal health while addressing the significant economic and healthcare burdens associated with premature birth. The company's proprietary proteomics and bioinformatics platform underpins its pipeline of innovative diagnostic tests, including the PreTRM® Test, which provides physicians with critical information to identify women at higher risk for spontaneous premature delivery. By enabling earlier proactive interventions, Sera seeks to enhance pregnancy care and reduce healthcare delivery costs.

YourBio Health is focused on revolutionizing the blood sampling and testing process to enhance the interaction between diagnostic medicine and healthcare consumers. The company has developed a blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy (TAP) technology, the device enables users to collect blood from their upper arm with a simple push of a button, facilitating easy and rapid diagnostic testing in various settings. This innovative approach aims to eliminate barriers in acquiring critical diagnostic information, thereby promoting informed healthcare delivery and empowering patients to take an active role in their well-being. By integrating TAP technology with a range of diagnostic assays, YourBio Health seeks to improve both patient and clinician experiences in the healthcare landscape.

ClearPath Diagnostics is a pathologist-owned tissue pathology and cytology practice based in Syracuse, New York. The company provides a range of diagnostic services, including cytology and pathology, to healthcare providers and their patients across the United States. Its offerings include testing for human papillomavirus (HPV) using the Digene Hybrid Capture 2 method, as well as tests for gonorrhea and chlamydia. Additionally, ClearPath provides supplemental tissue diagnostics, such as immunohistochemistry and frozen section analysis. The company also specializes in triple testing to identify common vaginitis pathogens and offers Vysis UroVysion testing for non-invasive assessment of bladder cancer. ClearPath Diagnostics analyzes cells from various organs, including breast and thyroid fine needle aspirations and urine specimens. Founded in 1975, it has been operating as a subsidiary of Laboratory Corp. of America Holdings since October 2016.

Sequenom, Inc. is a life sciences company focused on developing and commercializing molecular diagnostics testing services primarily for the women's health and oncology markets. It offers a range of laboratory-developed tests (LDTs), including the MaterniT21 PLUS, a noninvasive prenatal test (NIPT) that detects fetal chromosomal abnormalities through maternal blood samples. Other key products include the MaterniT21 GENOME test for detecting genomic deletions or duplications, the HerediT cystic fibrosis carrier screening test, and the SensiGene fetal Rhesus D test for determining the RhD factor in pregnant women. Additionally, Sequenom provides microarray tests under the NextView brand and various carrier screening tests for specific genetic disorders. The company serves physicians and client laboratories, and it has collaborated with Recombine Inc. Founded in 1994, Sequenom is headquartered in San Diego, California, and operates as a subsidiary of Laboratory Corporation of America Holdings.

Emulate, Inc. specializes in organ-on-chip technology that simulates human biology to enhance the understanding of how diseases, medications, chemicals, and food impact human health. The company develops organ-chips for various organs, including the lung, intestine, liver, and skin, which replicate normal functions and disease conditions. Emulate's innovative technology offers researchers a more accurate alternative to traditional experimental methods, such as cell cultures and animal testing, by providing detailed insights into human biological responses. Additionally, the company supplies drug development and instrumentation software to facilitate research and development workflows for its clients. Emulate serves a diverse range of sectors, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic institutions. Founded in 2013 and headquartered in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. until its name change in 2014.

ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases with targets in heart, liver, and neurodegenerative indications. It was founded in 2014 and is based in Boston, Massachusetts.

Calif.-based laboratory firm

Safe Food International (SFI) is an organization based in Washington, D.C., dedicated to enhancing global food safety through the collaborative efforts of consumer organizations. It aims to address common food safety issues by facilitating the development and implementation of national food safety programs. SFI works to ensure that these programs effectively approve food products prior to consumption or export, while also promoting measures to prevent intentional contamination of food supplies. Through awareness programs and strategic initiatives, SFI strives to create a safer food environment for consumers worldwide.

Ativa Medical is a medical device manufacturing company that is working to make diagnostic test results available in moments, rather than hours and days. The company specializes in the fields of medical device development, point of care diagnostics, microfluidics, and hematology. The company was founded in 2008 and headquartered in Saint Paul, Minnesota.

Bode Technology Group, Inc serves the law enforcement and identification markets and is unique in providing both state-of-the-art human DNA analysis and innovative DNA collection products. The range of Bode’s services include diverse offerings such as high throughput DNA testing services, casework analysis, missing person identification, private and CODIS databanking of convicted offenders or arrestees, as well as paternity and non-forensic identification. Their patented DNA collection systems are in use worldwide for collections of DNA from convicted offenders and arrestees, from crime scenes, as well as from parents and children for genealogy and identification services. Their analysts and their research and development teams are constantly looking for better ways to bring previously unused approaches and technologies into the labs for routine use for analysis of challenging samples – be it bones or aged, decayed tissue. On the strength and experience of their research and development teams and casework analysts, Bode is able to offer worldwide DNA analysis services, consulting, training, and validation services on a customized basis.

Vivify Health Inc. operates a cloud-based, device-agnostic software platform that facilitates home-based remote monitoring, connecting healthcare providers with patients through consumer electronics. This platform aims to reduce hospital readmissions and associated healthcare costs by enabling virtual interactions between patients and doctors. Vivify Health offers various personal health devices, including tablets, weight scales, and pulse oximeters, to support its remote care management solutions. Founded in 2009 and based in Plano, Texas, the company was formerly known as Intuitive Health, Inc. and rebranded in May 2013. Vivify Health operates as a subsidiary of Optum, Inc., following a transaction announced in December 2019. Through its technology, the company seeks to enhance population health, optimize patient engagement, and improve overall patient satisfaction while facilitating the expansion of physician practice services.

Covance Inc. is a contract research organization that offers comprehensive early and late-stage services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1987 and headquartered in Princeton, New Jersey, Covance provides a variety of drug development services, including preclinical and clinical pharmacology, biomarker services, and full management of Phase II and III clinical studies. The company is recognized for its expertise in laboratory testing across the chemical, agrochemical, and food sectors, and it is a leader in toxicology, central laboratory services, and clinical trial management. Covance's extensive experience enables it to deliver high-quality nonclinical, clinical, and commercialization services that help clients reduce the time and costs associated with bringing new drugs to market. The company has played a significant role in the development of many of the top prescription drugs available today, underscoring its vital contribution to advancing healthcare.

LipoScience is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. Its first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 8 million NMR LipoProfile tests have been ordered.

YourBio Health is focused on revolutionizing the blood sampling and testing process to enhance the interaction between diagnostic medicine and healthcare consumers. The company has developed a blood collection device that allows for convenient and virtually painless blood testing. Utilizing its proprietary Touch Activated Phlebotomy (TAP) technology, the device enables users to collect blood from their upper arm with a simple push of a button, facilitating easy and rapid diagnostic testing in various settings. This innovative approach aims to eliminate barriers in acquiring critical diagnostic information, thereby promoting informed healthcare delivery and empowering patients to take an active role in their well-being. By integrating TAP technology with a range of diagnostic assays, YourBio Health seeks to improve both patient and clinician experiences in the healthcare landscape.

Performance, Visibility. Simplicity...It's time for a beautiful network. Stateless is transforming network operations for software-centric networking. Tying together deep network understanding with state-of-the-art distributed systems, cloud, data science and gaming expertise, Stateless transforms network visibility, performance and response and helps accelerate the transition to modern network platforms, tying together physical and virtual layers. Focused on the enterprise data center, Stateless currently partners with the world’s leading network and infrastructure vendors (including VMware (VMW), Cisco Systems (CSCO), Cumulus Networks and others) to deliver solutions to some of the world’s largest private data center operators. We’re looking for software and networking engineers in Greater Seattle and the Bay Area with expertise in one or more of the following areas: Distributed Systems, Service Oriented Architecture, Complex Event processing, Functional Programming, Virtualization, Network design and deployment, Network programming, Network troubleshooting, configuration and performance tuning and SDN. Bonus points for experience working with cloud infrastructure (AWS, Azure, OpenStack) or low-level systems software (linux kernel, hypervisors, compilers/language runtimes), complex gaming systems or graphics and computational geometry. For more information visit http://www.statelessnetworks.com/ or follow Stateless on Twitter: @statelessntwrks.see

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.

SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

MEDTOX Scientific operates a certified drug testing and clinical laboratory that provides a range of forensic and clinical laboratory services. Catering to physician offices, corporations, clinics, health organizations, and government agencies, the company specializes in medical drug monitoring, pain management, clinical toxicology, therapeutic drug monitoring, emergency toxicology, pediatric lead testing, forensic toxicology, and employment drug testing. The laboratory is committed to delivering efficient and effective testing programs while prioritizing excellent customer service and strong client relationships. With a focus on responsiveness and adaptability, MEDTOX ensures that it meets the diverse needs of its clients.

Clearstone Central Laboratories is the largest and most experienced private company.

Orchid Cellmark Ltd. provides genotyping and DNA testing services for forensic, human identity testing, and agricultural applications.

Sanofi Genzyme is the specialty care global business unit of Sanofi, primarily dedicated to addressing the challenges posed by rare diseases, multiple sclerosis, immunology, and oncology. Established in 1981 as Genzyme in Boston, the company grew to become a major player in biotechnology, known for pioneering treatments for rare genetic disorders. In 2011, Genzyme was integrated into Sanofi, enhancing its capabilities in developing therapies for complex conditions that are often difficult to diagnose and treat. Sanofi Genzyme emphasizes a patient-centered approach, collaborating closely with healthcare providers and patient communities to advance new therapies. Over the years, its focus has expanded beyond rare diseases to include significant contributions in multiple sclerosis, oncology, and immunology, reflecting a commitment to innovation and improving patient outcomes across diverse therapeutic areas.

Genzyme Genetics is an industry leading provider of reproductive and oncology testing in the United States.

DCL Medical Laboratories, Inc. provides a range of laboratory testing solutions, specializing in anatomic and molecular pathology services. The company offers diagnostic cytopathology and histopathology, as well as immunohistochemistry services that include a variety of antibodies for biomarker analysis and customized methodologies for processing biopsy specimens. DCL Medical Laboratories also supports clinical trials and delivers reference testing focused on women's health, including ThinPrep Pap test processing, HPV molecular testing, and screening for chlamydia, gonorrhea, and cystic fibrosis carriers. Serving the medical industry across the United States, DCL Medical Laboratories aims to enhance diagnostic accuracy and patient care through its comprehensive testing services.

Monogram Biosciences specializes in developing and commercializing innovative products aimed at improving the treatment of infectious diseases, cancer, and other serious health conditions. The company is known for its Trofile molecular assay, which identifies the tropism of a patient's HIV, facilitating more personalized treatment options. Additionally, Monogram offers VeraTag technology, designed to accelerate the development of targeted therapeutics. By serving healthcare providers and pharmaceutical companies, Monogram plays a vital role in enhancing treatment strategies and advancing the understanding of complex diseases.

Tandem Labs is a bioanalytical contract research organization based in Salt Lake City, Utah, that supports pharmaceutical and biotechnology companies in their clinical and preclinical drug development programs. Founded in 1995, Tandem Labs specializes in mass spectrometry and immunochemistry services, offering a range of bioanalytical studies. The company develops, validates, and performs spectrometry-based methods in compliance with Good Laboratory Practice (GLP) standards, providing services such as method development and validation, dose formulation analysis, and clinical sample analysis. Additionally, Tandem Labs delivers immunoanalytical services and biomarker services, catering to both GLP and non-GLP discovery needs. The organization was acquired by LabCorp in January 2008, further enhancing its capabilities in drug development support.

DSI Laboratories is an operator of a medical laboratory. it is a full-service medical reference and toxicology laboratory that offers clinical testing, histology, chemistry, cytology, microbiology, and molecular medicine testing services.

Litholink Corp providing the highest level of customer support for our 24-hour urine testing services. Our national infrastructure allows for a seamless, integrated service that makes it easier for clients to manage their laboratory needs.

Esoterix is a laboratory services company that specializes in high-quality scientific testing and customer support. The company provides a range of assays and profiles through its facilities located in the United States and Western Europe. In addition to standard laboratory testing, Esoterix offers services tailored for physician specialists and clinical trials. The company also supports its operations with ancillary services, including information technology, managed care, and billing solutions, ensuring a comprehensive approach to laboratory testing and customer service.

US Pathology Labs provider of anatomic pathology and oncology testing services with a focus on the outpatient market.

Dianon Pathology offers a broad array of testing procedures, combining the expertise of an academic-based center with the personal service of a local pathologist. Their services include dermatopathology, gastrointestinal pathology, and uropathology.

Dynacare is an independent clinical laboratory offering services in certain regions of the U.S. and Canada. It operates 26 central laboratories (two of which are esoteric), 115 rapid response labs and 302 patient service centers in 21 states and two Canadian provinces.

Path Lab also has cooperative testing arrangements with a number of area hospitals to enhance service levels and optimize the use of local testing capacity.

ViroMed Laboratories, a member of LabCorp's Specialty Testing Group, is an FDA-registered laboratory that provides infectious disease testing in support of our human cells, tissues and cellular and tissue-based products (HCT/Ps) donor clients.

Allied Clinical Laboratories, Inc. provides testing services to physicians, hospitals, and health care providers.

Outcomes4Me Inc. is an AI-driven healthcare platform based in Cambridge, Massachusetts, founded in 2017. It focuses on empowering cancer patients by providing access to personalized, evidence-based treatment options and clinical information. The platform enables patients to navigate their care proactively, facilitating informed decision-making and improving health outcomes. By democratizing healthcare, Outcomes4Me promotes health equity and supports deeper insights into patient care, while also accelerating research and access to innovative treatments. The company is led by a team of experienced professionals from various sectors, including healthcare, oncology, and technology, dedicated to enhancing the patient experience in cancer treatment.